OCT 29, 2014 06:00 AM PDT
Nanotechnologies for Precision Medicine
Presented at the Cancer: Research, Discovery and Therapeutics Virtual Event
64 50 2652

Speakers:
  • Director, NSF IGERT Nanomedicine Science and Technology Program, Director, Electronic Materials Research Institute, Arts and Sciences Distinguished Professor of Physics, Lecturer on Radiation
    Biography
      Srinivas Sridhar is Arts and Sciences Distinguished Professor of Physics at Northeastern University, and Visiting Professor of Radiation Oncology, Harvard Medical School. He is the Director and Principal Investigator of Nanomedicine Science and Technology, an IGERT (Integrative Graduate Education and Research Training) program funded by the National Cancer Institute and the National Science Foundation. He is the founding director of the Electronic Materials Research Institute, an interdisciplinary center with research and education thrusts in nanophotonics and nanomedicine. From 2004 to 2008 he served as Vice Provost for Research at Northeastern University, overseeing the Universitys research portfolio. An elected Fellow of the American Physical Society, Sridhars current areas of research are nanomedicine and nanophotonics. He has published more than 160 articles on his work in nanomedicine, nanophotonics, metamaterials, quantum chaos, superconductivity and collective excitations in materials.

    Abstract:
    The modern era of Precision Medicine requires targeted delivery of molecular inhibitors that control key processes in disease pathways. PARP (Poly ADP Ribose Polymerase) plays a crucial role in the DNA repair pathways in a cell, rendering it the Achilles Heel specifically in cancer cells. We have developed novel injectable nanoformulations of PARP inhibitors that have superior bioavailability and tumor accumulation compared with available oral formulations. Extensive in vitro and in vivo studies have been carried out in ovarian, breast and prostate cancer models. These results imply an important role for the PARPi nanoformulations as chemo and radio-sensitizers enabling mono- and combination nanotherapeutic approaches for several cancers.

    Theranostic nanoplatforms combine multiple functionalities including multi-modal imaging, targeting to the disease site, and delivery of the drug payload through sustained as well as triggered drug release. We discuss the applications of these nanoplatforms in local chemotherapy with INCERT implants, and MR/SPECT/optical multi-modal imaging using iron oxide nanoparticles.

    Supported by the National Science Foundation, National Cancer Institute, DoD CDMRP, Mazzone Foundation and CIMIT.

    Show Resources
    Loading Comments...